SCHEMBL5928770

SCHEMBL5928770

CC1=NN(c2ccc([N+](=O)[O-])cc2)C(=O)C1C=O

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 13/20 0.67
▸ MEN1 O00255 12/20 0.67
▸ KMT2A Q03164 12/20 0.67
▸ ALDH1A1 P00352 10/20 0.67
▸ KDM4E B2RXH2 6/20 0.54
▸ ABCG2 Q9UNQ0 1/20 0.48
▸ PKM P14618 1/20 0.48
▸ SMN1; SMN2 Q16637 3/20 0.47
▸ AMY1A P0DUB6 1/20 0.44
▸ POLB P06746 2/20 0.44
▸ PSMD14 O00487 1/20 0.43
▸ NSD2 O96028 1/20 0.43
▸ DNMT1 P26358 1/20 0.43
▸ RXFP1 Q9HBX9 1/20 0.43
▸ ACHE P22303 1/20 0.42
▸ HSD17B10 Q99714 1/20 0.42
▸ L3MBTL1 Q9Y468 2/20 0.42
▸ THRB P10828 1/20 0.42
▸ HTT P42858 2/20 0.41
▸ GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5928903 0.84 MAPT (0.48) MAPTMEN1KMT2AALDH1A1KDM4E
SCHEMBL1934404 0.80 MAPT (1.00) MAPTMEN1KMT2AALDH1A1KDM4E
SCHEMBL5928736 0.80 MAPT (0.49) MAPTMEN1KMT2AALDH1A1KDM4E
SCHEMBL5928818 0.77 MEN1 (0.50) MAPTMEN1KMT2AALDH1A1KDM4E
SCHEMBL26821039 0.77 MAPT (0.76) MAPTMEN1KMT2AALDH1A1KDM4E
SCHEMBL26821077 0.76 MAPT (0.59) MAPTMEN1KMT2AALDH1A1KDM4E
SCHEMBL22670032 0.76 POLB (0.49) MAPTMEN1KMT2AALDH1A1KDM4E
SCHEMBL22678453 0.74 MAPT (0.41) MAPTMEN1KMT2AALDH1A1KDM4E
SCHEMBL22670353 0.73 ACSS2 (0.48) MAPTMEN1KMT2AALDH1A1KDM4E
SCHEMBL28700332 0.71 MAPT (0.58) MAPTMEN1KMT2AALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060229324-A1 Quinazolin-4-one derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2006-10-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060229324-A1 Quinazolin-4-one derivatives HPGDS, PTGS1, PTGDR MAPT 4875/4885MEN1 3991/4885KMT2A 2207/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback